NCT02783794View on ClinicalTrials.gov

BP-C1 in Short-term Treatment of Patients With Metastatic Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

December 24, 2012

Primary Completion Date

February 28, 2014

Study Completion Date

February 28, 2014

Conditions
Metastatic Breast CancerStage IV Breast Cancer
Interventions
DRUG

BP-C1

BP-C1, 0.05% solution for injection; doses: 0.035 mg/kg body weight (0.07 mL/kg) intramuscularly once daily for 32 consecutive days

DRUG

Placebo

Placebo, solution for injection; doses: 0.07 mL/kg body weight intramuscularly once daily for 32 consecutive days

Trial Locations (6)

Unknown

Russian Oncological Research Centre n.a. N.N. Blokhin, Russian Academy of Medical Science (RAMS), Moscow

"State Budgetary Institution of Nizhniy Novgorod Region Oncology Dispensary of Nizhniy Novgorod (Branch nr.1)", Nizhny Novgorod

Leningrad Regional Oncological Centre, Saint Petersburg

St. Petersburg State Budgetary Health Organization, City Clinical Oncology Dispensary, Saint Petersburg

Siriraj Hospital, Mahidol University, Bangkok

Udon Thani Cancer Hospital, Udon Thani

Sponsors

Lead Sponsor

Meabco A/S

Collaborators (1)

Meddoc
All Listed Sponsors
collaborator

Meddoc

OTHER

collaborator

Norwegian University of Life Sciences

OTHER

lead

Meabco A/S

INDUSTRY

NCT02783794 - BP-C1 in Short-term Treatment of Patients With Metastatic Breast Cancer | Biotech Hunter | Biotech Hunter